Selank for Health & Longevity

Evidence Review created on 08/06/2026 using AI4L / Opus 5

Also known as: TP-7, Selanc, Selank Acetate, TKPRPGP

Motivation

Selank is a short, seven-amino-acid peptide developed in Russia in the 1990s as a more stable version of a naturally occurring immune-signalling fragment of human antibodies. It is supplied as nasal drops and is registered in Russia as a prescription treatment for anxiety, where it is described as calming without drowsiness, memory dulling, or dependence. Outside Russia it holds no marketing approval and circulates mainly through unregulated suppliers.

Interest among people focused on long-term health comes from an unusual pairing: the peptide appears to act on the brain’s main calming signalling system while also shifting immune and inflammatory signalling, two areas that both change with age. Its human evidence base, however, is small, almost entirely Russian, and produced largely by the institution that created it.

This review examines what the published human and animal research shows about Selank’s effects on anxiety, mental drive, and immune signalling; how it is dosed, cycled, and sourced; which safety and quality questions remain open; and how strong the underlying evidence actually is.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

A curated set of sources that give a high-level, substantive overview of Selank from clinical, mechanistic, regulatory-critical, and practical angles.

• Selank: Benefits, side effects, dosage details, and how it works - Dan Min

  The most complete practitioner-informed practical guide available in English, covering dosing for both nasal and injectable forms, reconstitution and storage, cycling, and where pharmaceutical-grade versus laboratory-grade material comes from. It is unusual in drawing on interviews with clinicians who actually prescribe the peptide rather than only on the published literature.

• Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity - Vyunova et al., 2018

  The primary experimental source for the claim that Selank’s anxiolytic (anxiety-reducing) action works through positive allosteric modulation (a compound making a receptor respond more strongly to its natural signal) at the GABA-A receptor (gamma-aminobutyric acid type A receptor, the docking site for the brain’s main calming chemical messenger). It also reports the surprising finding that Selank can block the receptor-modulating activity of diazepam and olanzapine, which complicates the simple “benzodiazepine-like” story (benzodiazepines are the long-established class of prescription calming and sedating drugs, such as diazepam and alprazolam).

• Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank - Doyno & White, 2021

  The most useful sceptical counterweight in the English literature, written by pharmacists outside the Russian research network. It places Selank alongside other calming compounds sold to consumers without approval and argues explicitly that its abuse and dependence potential has never been properly characterised.

• Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia - Zozulya et al., 2008

  The pivotal human comparison behind Selank’s Russian registration, testing it against the benzodiazepine medazepam in 62 patients and linking clinical response to a blood marker of how fast the body destroys its enkephalins (short natural pain- and mood-regulating peptides). Reading it directly rather than through later summaries makes the study’s open-label design and absence of a placebo arm visible.

• Functional Connectomic Approach to Studying Selank and Semax Effects - Panikratova et al., 2020

  The only published brain-imaging study of Selank in healthy people, showing changes in the coupling between the amygdala (the brain’s threat-detection hub) and the right temporal cortex within twenty minutes of dosing. It is valuable because it tests the compound in a healthy population rather than a patient group, which is closer to how it is actually used.

Note on priority experts: No content on Selank was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, or Lifespan.io. Each platform’s own search function was queried directly and each returned no results for the term. Selank is a Russian-registered prescription peptide with almost no English-language clinical literature, and none of these outlets has covered it. The list has therefore been filled with the highest-quality non-priority sources available and has not been padded with vendor marketing pages or clinic blog posts, which make up the bulk of the remaining English-language material.

Grokipedia

Selank

Provides a structured overview of the peptide’s chemistry, its derivation from tuftsin (a small natural immune-signalling fragment of antibodies), its Russian development history, and its regulatory position, with the amino acid sequence and mechanistic claims laid out in one place. It is a useful orientation document because it aggregates the scattered Russian-language claims into a single readable entry.

Examine

No Examine article exists for Selank. A direct search of examine.com returns no results for the term.

Selank is a prescription medication in its country of registration and is not sold as a dietary supplement in regulated markets. Examine.com’s coverage is centred on dietary supplements and nutrition, and it does not typically cover prescription medications or unapproved peptide drugs.

ConsumerLab

No ConsumerLab article exists for Selank. A direct search of consumerlab.com returns no results for the term.

Selank is a prescription peptide medication rather than a retail dietary supplement, and ConsumerLab does not typically cover prescription medications; its independent testing programme is built around supplement products sold through ordinary retail channels.

Systematic Reviews

No systematic reviews or meta-analyses for Selank were found on PubMed as of August 6, 2026.

Mechanism of Action

Selank is a synthetic heptapeptide (a chain of seven amino acids) with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its first four residues reproduce tuftsin, a natural four-amino-acid fragment released from the heavy chain of IgG (immunoglobulin G, the most abundant antibody type in blood), which stimulates macrophages and neutrophils (two classes of white blood cell that engulf and destroy invaders). Tuftsin itself is destroyed within seconds in the bloodstream, so the designers at the Institute of Molecular Genetics of the Russian Academy of Sciences extended it at one end with Pro-Gly-Pro, a proline-rich tail that resists the enzymes which normally chop peptides apart. Almost all of the mechanistic work described below comes from that institute and its partner, the V.V. Zakusov Research Institute of Pharmacology, both of which developed, patented, and hold a direct institutional interest in the compound.

Four mechanisms are proposed, and they are not mutually exclusive.

• Positive allosteric modulation of the GABA-A receptor. Radioligand binding work, which measures how strongly a compound sticks to a receptor, reports that Selank increases GABA binding at its receptor without occupying the GABA site itself, in a way that depends on receptor subtype and concentration (Vyunova et al., 2018). Gene-expression work supports this: a single dose alters the expression of 45 of 84 neurotransmission-related genes in rat frontal cortex within one hour, with a pattern that correlates with the pattern produced by GABA itself (Volkova et al., 2016).

• Inhibition of enkephalin-degrading enzymes. Selank blocks the enzymes that break down enkephalins (the body’s own short opioid-like peptides) in human blood plasma, with half-maximal inhibition at roughly 15 micromolar, outperforming the reference inhibitors bacitracin and puromycin (Zozulya et al., 2001). This would raise and prolong the body’s own opioid-like signalling rather than acting on opioid receptors directly. The opioid contribution is not merely theoretical: naloxone, an opioid blocker, abolishes some of Selank’s behavioural effects in mice (Meshavkin et al., 2006).

• Immune and inflammatory signalling. Retaining the tuftsin core, Selank shifts the expression of inflammation-related genes in spleen and changes the balance of cytokines (signalling proteins released by immune cells). In rats under social stress it lowered interleukin-1-beta, interleukin-6, tumour necrosis factor-alpha, and transforming growth factor-beta-1 toward control values (Yasenyavskaya et al., 2021).

• Nerve-growth and monoamine effects. Selank alters brain levels of the monoamines (the small-molecule messengers serotonin, dopamine, and noradrenaline) and their metabolites, and modifies BDNF (brain-derived neurotrophic factor, a protein that supports the survival and growth of nerve cells) in the hippocampus and prefrontal cortex.

Competing mechanistic explanations. The GABA-A story and the enkephalin story are in genuine tension. If Selank were a straightforward benzodiazepine-like modulator, it should add to diazepam’s effect at the receptor; instead it blocks diazepam’s and olanzapine’s modulatory activity in binding assays, implying overlapping but non-identical binding sites (Vyunova et al., 2018). A third possibility argues against Selank being the active agent at all: its breakdown product Gly-Pro reproduces much of the parent peptide’s effect on immune gene expression, so some of what is attributed to Selank may be the work of a dipeptide fragment (Kolomin et al., 2014). Sceptics outside the Russian network group Selank with other GABA-active consumer compounds and argue that its receptor pharmacology has not been characterised well enough to predict abuse or withdrawal liability (Doyno & White, 2021).

Key pharmacological properties.

• Half-life: Approximately 2 minutes in blood. This is extremely short and creates the compound’s central paradox: measurable clinical effects persist for days after a course ends, so the peptide must be acting as a trigger for downstream changes in gene expression and receptor state rather than through sustained receptor occupancy.
• Selectivity: Low. Selank touches GABAergic, opioid, monoamine, and immune signalling simultaneously. It is a broad regulatory peptide, not a targeted drug.
• Tissue distribution: Absorbed rapidly across the nasal mucosa with a reported absolute bioavailability (the share of a dose reaching the bloodstream intact) near 93%, appearing in plasma within about 30 seconds and crossing into brain tissue. Injected subcutaneously it distributes systemically but nasal delivery is the registered and better-characterised route.
• Metabolism: Enzymatic hydrolysis by peptidases (aminopeptidases and related peptide-cleaving enzymes) in plasma and tissue, yielding shorter fragments including Gly-Pro. Selank is not a substrate for the cytochrome P450 system (the family of liver enzymes, including CYP3A4, that processes most conventional oral drugs), which is why classic pharmacokinetic drug interactions (one drug changing how much of another reaches the blood) are unlikely.

Historical Context & Evolution

• Original intended use. Selank’s ancestor, tuftsin, was identified at Tufts University in 1970 as an immune-stimulating fragment of antibody molecules that activates macrophages and neutrophils. Its intended applications were infectious and oncological, not psychiatric; the tetrapeptide’s clinical development stalled because it is destroyed almost instantly in blood. Selank was created in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences, jointly with the V.V. Zakusov Research Institute of Pharmacology, purely as a chemical solution to that stability problem (Siebert et al., 2017).

• The pivot to anxiety. The anxiolytic effect was an observation, not the design goal. Once the stabilised analogue was in hand, behavioural screening found it reduced anxiety-like behaviour in rodents without the sedation and motor impairment that benzodiazepines produce. That observation, plus the finding that anxious patients have shortened enkephalin half-life in blood, redirected the entire programme toward anxiety and asthenic conditions (states of persistent mental and physical exhaustion).

• What the historical research actually found. The registration-supporting studies are worth describing on their own terms rather than summarising as “positive”. In 62 patients with generalized anxiety disorder (a condition of persistent, excessive worry that is difficult to control) and neurasthenia (a syndrome of chronic mental and physical fatigue), Selank produced anxiety reduction comparable to the benzodiazepine medazepam, but with additional anti-fatigue and mild activating effects that the comparator lacked, in an open-label design where both patient and investigator knew which treatment was given, and it raised the blood half-life of leucine-enkephalin in the patients who responded (Zozulya et al., 2008). A later 60-patient comparison against phenazepam reported that the anxiolytic effect persisted about a week after the last dose (Medvedev et al., 2014). A 70-patient study used Selank as an add-on to phenazepam and reported faster symptom improvement plus reduced benzodiazepine side effects during treatment and after withdrawal (Medvedev et al., 2015). Selank was registered in Russia in 2009 as a 0.15% nasal drop solution.

• The evolution of opinion, and what changed. No Western regulator has evaluated Selank for approval, and no independent group outside the Russian network has replicated the clinical findings in the seventeen years since registration. That is a genuine absence of evidence rather than a refutation: the trials have not been shown to be wrong, they have simply never been repeated under blinded, placebo-controlled conditions by parties without an interest in the outcome. What has changed on the sceptical side is the appearance of regulatory attention. The United States Food and Drug Administration (FDA, the agency that approves and regulates medicines in the United States) now carries selank acetate (TP-7) on its page of bulk drug substances that may present significant safety risks in compounding — in the table of substances whose nomination was withdrawn by the nominators rather than in the active category 2 list — citing the potential for aggregation (peptide molecules clumping together) and peptide-related impurities and stating that it lacks information on safety in humans (FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks). What has changed on the supportive side is the emergence of independent-country mechanistic work and the first healthy-volunteer brain-imaging data. Neither side’s position is settled.

Expected Benefits

Benefits are framed for a risk-aware adult who is already optimising sleep, training, and nutrition and is considering Selank as a targeted addition, not for a general population seeking treatment of a diagnosed illness.

High 🟩 🟩 🟩

No benefit of Selank currently meets this evidence threshold. There are no meta-analyses, no placebo-controlled trials of any clinical outcome — the single placebo-controlled human study measured brain connectivity rather than symptoms — and no independently replicated human outcomes for any claimed effect.

Medium 🟩 🟩

Reduction of Anxiety Symptoms

The most consistently reported effect, and the one on which Russian registration rests. Three human comparative trials, using standard psychometric scales, report anxiety reduction of the same order as benzodiazepine comparators over 14-day courses, with the effect appearing within the first days rather than after weeks. The proposed mechanism is combined positive allosteric modulation at the GABA-A receptor plus preservation of the body’s own enkephalins. The critical limitation is design: these were open-label comparative trials without placebo arms, all conducted by or with the institutes that developed the compound, in patients with diagnosed anxiety disorders rather than in healthy high-performers, and none has been replicated independently.

Magnitude: In the 62-patient registration comparison, anxiolytic effect was reported as equivalent to medazepam over 14 days, with additional antiasthenic and mild activating effects the comparator did not produce; in a 60-patient comparison against phenazepam the anxiolytic effect persisted approximately one week beyond the last dose.

Reduced Benzodiazepine Burden When Used as an Add-On

For someone already on a benzodiazepine and trying to come off it, Selank has the best-supported role in its evidence base. Adding it to phenazepam produced faster improvement on depression and anxiety rating scales than the benzodiazepine alone, and lowered the incidence of the side effects that make benzodiazepines unattractive for cognitive performance: attention and memory impairment, sedation, excessive sleep duration, emotional flattening, and sexual dysfunction. Effects persisted through tranquilizer withdrawal. The evidence is a single 70-patient trial from the developing network, without a placebo arm.

Magnitude: In a 70-patient comparison (40 receiving the combination, 30 receiving phenazepam alone), the combination group showed earlier response on the depression rating scale and lower rates of the listed side effects both during treatment and after benzodiazepine withdrawal; absolute event rates were not reported.

Low 🟩

Antiasthenic and Mild Activating Effect

Selank is reported to reduce fatigue and increase drive rather than blunt them, which is the opposite of what conventional calming agents do and the property that makes it interesting for adults who must sustain cognitive performance. The proposed mechanism is stimulation of noradrenergic and dopaminergic signalling alongside the calming effect. The evidence basis is investigator observation within the anxiety trials and rodent motivation and learning studies, not a dedicated endpoint in any controlled study, and self-reported energy is exactly the domain where an unblinded design produces the largest inflation.

Magnitude: Not quantified in available studies.

Antidepressant-Like Mood Effect

Alongside the anxiolytic action, Selank is reported to lift depressed mood, an effect attributed to activation of the brain monoamine systems, increased dopamine synthesis and turnover, and modulation of tyrosine hydroxylase (the rate-limiting enzyme in dopamine and noradrenaline production) rather than to the GABA-A mechanism. The dedicated evidence is a rodent programme using two separate depression models, in which repeated high doses reversed immobility and anhedonia (loss of the capacity to feel pleasure) in a genetically depression-prone rat strain, and a single low dose shortened immobility in a situationally provoked mouse model, with no change in general locomotor activity to confound the reading (Sarkisova et al., 2008); a four-week rat study describes the same antidepressant component (Czabak-Garbacz et al., 2006). The only human signal is indirect: in the phenazepam add-on trial the combination group improved earlier on the depression rating scale than the benzodiazepine alone, which cannot separate a mood effect from the anxiolytic and side-effect-sparing effects already credited above. No trial has used depression as a primary endpoint in humans, and the rodent dose-response does not run in a single direction, which weakens any translation to a fixed human dose.

Magnitude: Not quantified in available studies. The rodent work reports direction of effect only, at 1000 to 2000 micrograms per kilogram repeated in the genetic model and 100 to 300 micrograms per kilogram as a single dose in the situational model; no human depression endpoint has been measured.

Absence of Sedation, Cognitive Blunting, and Dependence

Across the human trials and the rodent work, Selank has not produced the hypnosedation (sleep-inducing sedation), muscle relaxation, amnesia, tolerance, or withdrawal syndrome that define benzodiazepine use. For a longevity-oriented adult, this profile is arguably more valuable than the anxiolytic effect itself, because it is what would permit continued use without cognitive cost. The counterweight is that absence of reported dependence in short, small, unblinded studies is weak evidence of absence; pharmacists reviewing the compound have argued specifically that its abuse liability has never been formally assessed.

Magnitude: No cases of tolerance, dependence, or withdrawal syndrome were reported across the published human courses, which ran 14 to 30 days in cohorts of 30 to 70 patients; no formal abuse-liability study has been conducted.

Modulation of Inflammatory Signalling ⚠️ Conflicted

Because Selank retains the tuftsin core, it acts on immune cells as well as neurons, and this is the property with the clearest link to biological ageing, where chronically elevated inflammatory signalling is a central feature. In rats under social stress it normalised interleukin-1-beta, interleukin-6, tumour necrosis factor-alpha, and transforming growth factor-beta-1. In patients with anxiety-asthenic disorders dosed for 14 days it shifted the balance between the two main arms of the immune response (Uchakina et al., 2008). The evidence is directly conflicted, however: in the laboratory arm of that same publication, run on blood cells taken from patients with depression rather than on the dosed anxiety cohort, Selank at one concentration completely suppressed interleukin-6 gene expression while simultaneously raising interleukin-6 protein concentration in that same cell culture, so the direction of the effect on a single central inflammatory signal is not resolved.

Magnitude: In rodent social-stress models, elevated interleukin-1-beta, interleukin-6, tumour necrosis factor-alpha, and transforming growth factor-beta-1 were returned to approximately control values over 20 days; in humans, only directional shifts in the two-arm immune balance over 14 days have been reported (Uchakina et al., 2008), without effect sizes.

Speculative 🟨

Learning and Memory Support

Rodent work reports that Selank accelerates acquisition of avoidance learning in animals that learn poorly at baseline, improves object recognition in aged rats, and protects memory against alcohol-related impairment. There is no controlled human cognitive-performance study of any kind. The basis for this claim in humans is entirely mechanistic extrapolation from animal models plus uncontrolled user report.

Neurotrophic Support via BDNF ⚠️ Conflicted

Selank is widely described as raising BDNF, the growth factor most associated with neuroplasticity (the brain’s ability to rewire itself) and resilience against cognitive decline, and this is the basis of most longevity-framed marketing. The actual published finding runs the other way in the best-characterised experiment: in alcohol-exposed rats, Selank prevented an ethanol-induced increase in BDNF in hippocampus and frontal cortex, that is, it normalised a raised level rather than elevating a normal one. Whether Selank raises, lowers, or simply stabilises BDNF appears to depend on the baseline state of the animal, and no human BDNF data exist.

Stress-Protective Effects on Gut and Liver

In chronically stressed rats, Selank preserved the structure of the large intestine, shifted the composition of colonic microbiota away from the stress-associated pattern, and protected hepatocyte (liver cell) function and liver architecture. If these translate, they would be relevant to the gut-barrier and metabolic dimensions of ageing. No human gastrointestinal or hepatic endpoint has ever been measured.

Antiviral and Interferon-Inducing Activity

Because Selank retains the tuftsin core, it acts on antiviral immune signalling as well as on inflammatory signalling. In experimental influenza infection it suppressed viral reproduction in cell culture and raised survival in mice, most strongly when given before exposure, and it induced interferon-alpha gene expression (interferon-alpha is one of the body’s own antiviral signalling proteins) without shifting interleukin-4, interleukin-10, or tumour necrosis factor-alpha (Ershov et al., 2009); the same activity has been traced to short structural fragments of the peptide (Andreeva et al., 2010). For a longevity-oriented adult the question is not treating influenza but whether this arm of the mechanism supports the antiviral competence that declines with age. The basis is animal and cell-culture work from the developing network only, with no human infection, vaccination-response, or interferon endpoint ever measured.

Attenuation of Alcohol and Opioid Withdrawal

Selank reduces the aversive signs of withdrawal in animals made dependent on morphine or alcohol, which is the benefit domain most directly predicted by its enkephalin-preserving action rather than by its calming action at the GABA-A receptor. A single injection at an anxiolytic dose cut the total morphine-withdrawal index by roughly 40% in rats, suppressed convulsive reactions and posture disorders, and raised the tactile sensitivity threshold ninefold, performing close to diazepam (Konstantinopolsky et al., 2022); earlier rodent work reported attenuation of alcohol-withdrawal signs and of ethanol-induced behavioural sensitisation in the same direction. For a longevity-oriented adult the relevance is narrow but real, because it overlaps with the supervised benzodiazepine-reduction setting that carries the only human data in this review. No human withdrawal endpoint has ever been measured, so the basis is animal work from the developing network only.

Metabolic and Haemostatic Effects

In a rat model of metabolic syndrome, Selank improved haemostatic (blood-clotting) parameters, the lipid profile, and blood sugar. Related proline-containing peptides in the same family show anticoagulant and fibrinolytic (clot-dissolving) activity. This is a single-model animal finding with no human counterpart, and it is listed here as much for its risk implications as for its potential benefit.

Benefit-Modifying Factors

• Baseline anxiety level: The largest reported effects come from patients with diagnosed generalized anxiety disorder and shortened blood enkephalin half-life at baseline. In the registration study, the rise in enkephalin half-life during treatment correlated with anxiety severity, meaning that the further from normal a person starts, the more room there is to move. A calm, well-regulated adult should expect a substantially smaller effect than the trial numbers suggest.

• Baseline enkephalin and inflammatory status: Selank’s proposed mechanisms are both normalising rather than unidirectional. Enkephalin-degrading enzyme inhibition matters most when enkephalin turnover is abnormally fast, and the cytokine effects in animals consist of returning elevated values toward control. Someone with low high-sensitivity C-reactive protein (hs-CRP, a blood marker of body-wide inflammation) and normal interleukin-6 has less to normalise.

• Genetic polymorphisms: No pharmacogenetic study of Selank exists, so this is inference from mechanism. Because Selank is cleared by peptidases rather than the cytochrome P450 system, the usual metabolising-enzyme variants such as CYP2C9 and CYP2D6 are irrelevant. Variants plausibly relevant instead are in COMT (catechol-O-methyltransferase, the enzyme that clears dopamine and noradrenaline from the prefrontal cortex), where slow-clearing variants are associated with higher baseline anxiety and may interact with the monoamine component; in OPRM1 (the gene for the mu-opioid receptor, on which enkephalins act), where the A118G variant alters opioid-signalling sensitivity; and in the GABA-A receptor subunit genes, whose expression Selank itself alters. None of this has been tested.

• Sex-based differences: The Russian trials enrolled both sexes but published no sex-stratified outcomes, so no direct evidence exists. Two indirect considerations apply: anxiety disorders are roughly twice as prevalent in women and the immune-signalling systems Selank touches differ measurably between sexes, with women mounting stronger responses in the antibody-producing arm. Both would predict differential response, and neither has been examined.

• Pre-existing health conditions: Untreated thyroid dysfunction, iron deficiency, obstructive sleep apnoea (repeated breathing pauses during sleep), and blood-sugar instability all produce anxiety and fatigue that Selank would mask rather than correct, and correcting them first will produce a larger and more durable effect than any peptide. Conversely, in people with chronic low-grade inflammation, the immune-signalling arm of the mechanism has more to act on.

• Age-related considerations: The strongest longevity-relevant claims concern reversal of age-related memory disturbance and normalisation of the inflammatory signalling that rises with age, both of which imply greater headroom in older adults. Older monkeys retained the compensatory and anti-amnesic response in primate work. Against this, older adults have thinner, drier nasal mucosa and more frequent use of nasal corticosteroids and decongestants, all of which reduce and destabilise absorption from the registered nasal route.

Potential Risks & Side Effects

Risks are framed for an adult who will most likely obtain Selank outside a regulated pharmacy channel, since that is the realistic acquisition route outside Russia.

High 🟥 🟥 🟥

Unverified Identity, Purity, and Sterility of Non-Pharmaceutical Product

The dominant risk of Selank is not the molecule but the vial. Outside Russia there is no approved finished product, so material reaching users is overwhelmingly sold for laboratory use only, manufactured without pharmaceutical good-manufacturing-practice controls, and labelled “not for human consumption”. Such material is not required to meet identity, purity, endotoxin (fever-inducing fragments of bacterial cell walls), or sterility standards, and peptide synthesis routinely leaves truncated and modified peptide impurities that are difficult to detect without dedicated analysis. For an injectable preparation reconstituted at home, the consequences of a contaminated or non-sterile vial are immediate rather than theoretical.

Magnitude: Not quantified in available studies. The actual content of an unregulated vial is unknown by definition, and the FDA states plainly that it lacks the information needed to know whether compounded selank acetate would cause harm when administered to humans.

Absence of Long-Term and Independent Human Safety Data

Every published human course of Selank ran for 14 to 30 days in cohorts of 30 to 70 patients, all conducted by or with the developing institutes. There is no published English-language toxicology study, no chronic-exposure cohort, no pregnancy or fertility data, no carcinogenicity assessment, and no pharmacovigilance system (organised collection of side-effect reports after a medicine reaches the market) anywhere outside Russia. For an intervention framed as a long-term longevity tool, the mismatch between the intended duration of use and the duration over which safety has been observed is the central problem, and it cannot be resolved by the reassuring tolerability reports from short trials.

Magnitude: Maximum observed human exposure in the published literature is approximately 30 days; cumulative published human exposure across all trials is on the order of 200 patients, against zero long-term follow-up.

Medium 🟥 🟥

Immunogenicity from Aggregation and Peptide-Related Impurities

The FDA’s stated concern is specific: compounded drugs containing selank acetate may pose a risk of immunogenicity (the body treating the injected material as foreign and mounting an immune response against it) for certain routes of administration because of the potential for aggregation and peptide-related impurities. That response can range from injection-site inflammation to systemic hypersensitivity. The mechanism is well established for peptide therapeutics generally: clumped or impure peptide is far more likely to be recognised as foreign than clean monomeric peptide. This risk is concentrated in the injectable route and in improperly stored or agitated reconstituted solution; the registered nasal route carries substantially less of it.

Magnitude: Not quantified in available studies. The FDA identifies the hazard as a class property of peptides prone to aggregation, without an incidence estimate for selank acetate specifically.

Additive Central Nervous System Depression and Symptom Masking

Selank acts on the GABA-A receptor and on opioid-like signalling, and it demonstrably potentiates diazepam in animal models. Stacked with benzodiazepines, phenibut, alcohol, sedating antihistamines, or high-dose GABA-active supplements, the combined effect on alertness and respiratory drive is unpredictable, and the specific pharmacology of the interaction has never been characterised in humans. A second, subtler version of the same problem is symptom masking: relieving anxiety and fatigue pharmacologically can delay diagnosis of the thyroid disease, anaemia, sleep apnoea, or mood disorder actually generating the symptoms.

Magnitude: In rats under chronic mild stress, combined Selank and diazepam produced a greater anxiolytic effect than either agent alone; no human interaction study exists and no dose adjustment has been characterised.

Low 🟥

Local Nasal Irritation and Altered Smell or Taste

The registered formulation is a 0.15% aqueous solution instilled several times daily for 14 days, and the expected local effects of any repeated intranasal drug apply: transient stinging, dryness, congestion, sneezing, and post-nasal drip carrying a bitter taste. Blunted or distorted smell belongs to the same cluster and is reported less often; the proposed mechanism is the mucosal drying and congestion that obstruct odour molecules reaching the olfactory epithelium (the smell-sensing tissue high in the nasal cavity), not any direct action on the olfactory nerve, and it therefore tracks the irritation rather than outlasting it. These are the most commonly reported complaints in practical use. They are self-limiting and resolve on stopping, but repeated multi-week courses in dry environments can produce more persistent mucosal irritation.

Magnitude: Not quantified in available studies. The Russian human trials reported tolerability as good on the standard side-effect rating scale without publishing individual local-effect incidence rates.

Injection-Site Reactions with Subcutaneous Use

Where Selank is used as a reconstituted subcutaneous injection rather than nasally, the practitioner-reported side-effect profile matches that of therapeutic peptides generally: injection-site redness, swelling and discomfort, plus occasional nausea, headache, and dizziness. This route has no published clinical outcome trial support at all, since every human trial reporting symptom outcomes used intranasal administration; the only published human study to use injection was a brain-imaging experiment.

Magnitude: Not quantified in available studies. Reported by prescribing clinicians as comparable to other injectable therapeutic peptides, without incidence figures.

Speculative 🟨

Unpredictable Immune Modulation in Autoimmune Disease or Active Malignancy

Selank retains the immune-activating core of tuftsin and measurably alters the expression of genes governing complement activation (part of the immune system’s attack machinery), inflammasome signalling (an alarm system inside immune cells), and interleukin-2 receptor function. In an autoimmune condition, where the problem is an immune system already attacking self-tissue, deliberately perturbing these pathways in an uncharacterised direction is not obviously benign; the same applies where immunosuppressive therapy is being relied on. Clinicians prescribing peptides generally list active cancer as a contraindication on the same logic. There are no human data in either population, and the concern is entirely mechanistic.

Bleeding Tendency

Selank and related proline-containing peptides show anticoagulant and fibrinolytic activity in rats, and a metabolic-syndrome model reported changes in haemostatic parameters. If this translates to humans, the effect would be additive with anticoagulant and antiplatelet medication and with blood-thinning supplements. No human coagulation parameter has ever been measured on Selank.

Opioid-System Involvement and Reinforcement Potential

Selank’s anxiolytic effect is partly blocked by naloxone, meaning the body’s own opioid signalling participates in it. Pharmacists outside the developing network have argued that a compound acting on both GABA-A and opioid signalling, sold directly to consumers without approval, needs formal abuse-liability assessment before public access rather than after. No dependence, tolerance, or withdrawal has been reported in the published human courses, but none of those studies was designed to detect it.

Risk-Modifying Factors

• Genetic polymorphisms: No pharmacogenetic data exist for Selank. Because clearance is peptidase-mediated rather than cytochrome P450-mediated, variants in CYP2C9, CYP2D6, and CYP3A4 do not modify exposure, which removes a major source of interindividual risk that applies to most psychoactive drugs. Variants in OPRM1 (the mu-opioid receptor gene) could plausibly modify the opioid-mediated component and hence any reinforcement potential; human leukocyte antigen type (the inherited set of markers the immune system uses to tell self from non-self) governs immunogenic response to peptide impurities generally. Both are inference, not evidence.

• Baseline biomarker levels: Baseline hs-CRP and interleukin-6 matter because the immune effects appear to be normalising rather than unidirectional; an already-low inflammatory baseline offers no benefit and leaves only the possibility of pushing signalling in an unwanted direction. Baseline liver enzymes and complete blood count matter because they establish whether a later abnormality is attributable to the peptide or was present beforehand, which is otherwise impossible to determine with an unregulated product.

• Sex-based differences: No sex-stratified safety data were published from any trial. Women mount stronger antibody responses and experience roughly twice the rate of drug hypersensitivity reactions overall, which would predict a higher immunogenicity risk from impure injectable peptide. Selank has never been studied in pregnancy or lactation in any species reported in the accessible literature, so the peptide is contraindicated in both on grounds of absent data rather than known harm.

• Pre-existing health conditions: Autoimmune disease, active malignancy, and immunosuppressive therapy raise the theoretical stakes of the immune-modulating arm. Chronic rhinitis (persistent nasal inflammation), nasal polyps, recent nasal or sinus surgery, and habitual decongestant use all alter absorption from the nasal route and make dosing unpredictable. Bleeding disorders and anticoagulant therapy interact with the speculative haemostatic effects. A history of sedative or benzodiazepine use disorder is relevant to any GABA-active compound with uncharacterised reinforcement potential.

• Age-related considerations: Older adults carry the risks disproportionately. Polypharmacy multiplies the chance of additive central nervous system depression; thinner nasal mucosa alters absorption; immune senescence makes the direction of any immune perturbation harder to predict; and the absence of any published data in adults over 65 is near-total, since the trial populations were adults of working age. The one favourable signal is the primate work showing retained efficacy without additional adverse effects in older animals.

Key Interactions & Contraindications

Because Selank is cleared by peptidases and not by the cytochrome P450 system, the classic pharmacokinetic interactions that dominate drug interaction tables do not apply. The interactions that matter are pharmacodynamic (two agents acting on the same system).

• Benzodiazepines (diazepam, phenazepam, alprazolam, clonazepam, lorazepam): Caution, with a documented additive effect. Selank potentiated diazepam’s anxiolytic action in rodent chronic-stress models, and the Russian add-on trial deliberately exploited this combination. Clinical consequence is excessive sedation and impaired coordination when doses are not adjusted. Mitigation: where the combination is used deliberately under supervision, the published protocol reduced the benzodiazepine rather than the peptide; outside that setting the mitigating step is separation of the two agents.

• Phenibut and other GABA-active recreational compounds: Caution bordering on avoidance. Phenibut carries documented dependence and a severe withdrawal syndrome, and the two compounds are routinely stacked in the same online marketplaces. Clinical consequence is additive central nervous system depression against a background of uncharacterised reinforcement potential for both. Mitigation: no form of the combination is defensible on current evidence.

• Alcohol: Caution. Animal work shows Selank interacts substantially with ethanol systems, attenuating ethanol-induced hyperlocomotion (excessive movement) and withdrawal signs. Clinical consequence in humans is unknown but additive central nervous system depression is the default assumption. Mitigation: abstinence from alcohol for the duration of a course.

• Over-the-counter sedating antihistamines (diphenhydramine, doxylamine, chlorphenamine) and cough preparations containing them: Monitor. Clinical consequence is additive drowsiness and next-day cognitive impairment. Mitigation: substitution of a non-sedating antihistamine (loratadine, fexofenadine) for the duration of a course.

• Over-the-counter nasal decongestant sprays (oxymetazoline, xylometazoline) and intranasal corticosteroids (fluticasone, mometasone): Monitor, with a delivery rather than a systemic consequence. Vasoconstriction and altered mucosal surface change how much peptide is absorbed, making the delivered dose erratic. Mitigation: administration separated by at least 30 minutes, with Selank instilled first.

• Opioid analgesics (oxycodone, tramadol, codeine) and opioid antagonists (naltrexone, naloxone): Caution with agonists, loss of effect with antagonists. Selank raises the body’s own enkephalin levels by blocking their breakdown, and naloxone abolishes some of its behavioural effects. Clinical consequence is a theoretically additive opioid-tone effect with agonists and a blunted or absent response in anyone on low-dose naltrexone or naltrexone for alcohol use disorder. Mitigation: no measure is established for opioid agonists, so the combination has no defensible form; on an opioid antagonist the expected outcome is reduced or absent benefit.

• Anticoagulants and antiplatelet drugs (warfarin, apixaban, rivaroxaban, clopidogrel, aspirin): Caution on mechanistic grounds. Selank and related proline-containing peptides show anticoagulant and fibrinolytic activity in rats. Clinical consequence would be increased bleeding risk. Mitigation: contraindication in anyone anticoagulated; where use nevertheless occurs, monitoring of clotting parameters.

• Supplements with additive calming or GABA-active effects (GABA, L-Theanine, magnesium glycinate, valerian, kava, ashwagandha, glycine, taurine, high-dose melatonin): Monitor. Each of these is used for the same purpose as Selank, and combined use produces additive sedation that can be mistaken for a Selank effect. Mitigation: introduction of Selank against a stable supplement background, with one variable changed at a time.

• Supplements with additive blood-thinning effects (fish oil at high dose, nattokinase, Ginkgo biloba, garlic extract, high-dose vitamin E, curcumin): Monitor. These compound the speculative haemostatic effect. Mitigation: suspension of blood-thinning supplements around surgery or dental procedures while a Selank course is running.

• Immunosuppressants and immunomodulators (tacrolimus, ciclosporin, methotrexate, tumour necrosis factor inhibitors such as adalimumab): Avoid. Selank shifts inflammatory gene and cytokine signalling in a direction that is not fully characterised and may oppose the intended therapeutic effect. Mitigation: none reliable, so the combination has no defensible form.

• Other interventions (stacked peptides: Semax, BPC-157, TB-500, GHK-Cu): Caution. Selank is frequently stacked with Semax, another Russian heptapeptide from the same institute, and with BPC-157, TB-500, and GHK-Cu. Clinical consequence is an uncharacterised additive adverse-event profile compounded by attribution failure, since no combination has been studied in humans and stacking makes both benefit and adverse effect impossible to assign. Mitigation: a single peptide at a time. Non-pharmacological interventions with the same target, particularly cognitive behavioural therapy for anxiety, have far stronger evidence and no supply-chain risk.

Populations for whom Selank is contraindicated:

• Pregnancy and lactation, on grounds of complete absence of reproductive safety data in any species reported in the accessible literature.
• Anyone under 18, for whom no data exist and where GABAergic and immune systems are still developing.
• Active malignancy of any stage, and the first five years after treatment for a haematological malignancy, given the immune-activating tuftsin core.
• Active autoimmune disease requiring treatment, particularly systemic lupus erythematosus (an autoimmune disease in which the immune system attacks tissue in several organs at once), rheumatoid arthritis with active synovitis (inflammation of the joint lining), and inflammatory bowel disease in flare.
• Solid organ transplant recipients on any immunosuppressive regimen.
• Anyone on therapeutic anticoagulation, or with a platelet count below 100,000 per microlitre, or with a known bleeding disorder.
• Documented sedative, benzodiazepine, opioid, or alcohol use disorder, whether active or in remission within 12 months.
• Severe hepatic impairment (Child-Pugh Class B or C, a scoring system for the severity of liver disease) or advanced kidney disease (estimated glomerular filtration rate below 30 mL/min/1.73 m², a measure of kidney filtration capacity), where clearance of peptide fragments has never been characterised.
• Anyone with chronic rhinosinusitis, nasal polyposis, or nasal or sinus surgery within 90 days, for whom nasal absorption is unpredictable.

Risk Mitigation Strategies

• Nasal route rather than injection: Every published human trial reporting clinical outcomes used intranasal delivery, absolute bioavailability by that route is reported near 93%, and the route bypasses the immunogenicity, sterility, and injection-site risks that dominate the FDA’s stated concern. This single choice removes most of the High and Medium risks listed above.

• Pharmaceutical grade as the only mitigating grade: The mitigating condition is a finished pharmaceutical preparation (the registered 0.15% nasal solution) or, where a compounded product is used, one dispensed by a licensed compounding pharmacy against a valid prescription. Material labelled “for research use only” or “not for human consumption” mitigates nothing regardless of the vendor’s marketing, and this directly addresses the unverified identity, purity, and sterility risk.

• Lot-specific third-party certificate of analysis: The mitigating document is a certificate covering identity by mass spectrometry, purity by high-performance liquid chromatography (a laboratory separation method used to quantify purity) of at least 98%, and, for any injectable, sterility and bacterial endotoxin testing. A certificate that references the specific lot number on the vial, rather than the product generally, is what mitigates both mislabelled peptide and peptide-related impurity load.

• Baseline panel before the first dose: The mitigating measure is a pre-course panel comprising complete blood count, comprehensive metabolic panel, hs-CRP, thyroid-stimulating hormone with free thyroxine, ferritin, and fasting glucose and insulin, alongside a recorded validated anxiety score. Without a baseline it is impossible to attribute a later abnormality to the peptide or to distinguish a real effect from regression to the mean (the tendency of an unusually high or low measurement to drift back toward average on retest), and the panel screens out the treatable conditions Selank would otherwise mask.

• One course at a time with nothing else new: The mitigating pattern is a single course run against a stable background of sleep, training, nutrition, and supplements, with no other new agent begun within four weeks either side. This mitigates attribution failure, which is the most common practical error and the reason most people cannot tell whether the compound worked.

• Exposure capped at the studied duration: The mitigating limit is a course of 14 to 30 days, matching the longest human exposure for which any safety data exist, followed by an off period of at least equal length. This mitigates the absence of long-term safety data by keeping exposure inside the observed window rather than extrapolating past it.

• Hard separation from other central nervous system depressants: The mitigating rule is no alcohol, phenibut, sedating antihistamines, or unsupervised benzodiazepine use during a course. This mitigates the additive central nervous system depression risk, which is the interaction most likely to cause acute harm.

• Correct storage and scheduled discard of reconstituted solution: The mitigating handling protocol holds reconstituted material at approximately 4°C (39°F), leaves the vial unshaken and unagitated, and discards it after 30 days. Agitation promotes the peptide aggregation that underlies the FDA’s immunogenicity concern, and time-limited discard mitigates microbial growth in a preservative-limited solution.

• Defined stopping triggers: The mitigating triggers for immediate discontinuation and clinical evaluation are any systemic hypersensitivity sign (rash, facial or lip swelling, wheeze), any unexplained bruising or bleeding, persistent nasal bleeding, or new fever. Each corresponds to a specific listed risk (immunogenicity, haemostatic effect, mucosal injury, contamination), and none is a signal that dose adjustment addresses.

Therapeutic Protocol

• Standard registered protocol: The Russian marketing authorisation covers a 0.15% aqueous nasal solution. The protocol used by Russian psychiatrists and reflected in the registration trials is 2 drops into each nostril three times daily, giving approximately 300 micrograms per administration and 900 micrograms per day, for a course of 14 days. Courses have been extended to 30 days in the add-on studies. This is the only protocol with human outcome data behind it.

• Competing approach, compounded injectable: A parallel practice has developed in Western peptide clinics using reconstituted subcutaneous injection at approximately 0.5 mg daily, five days per week, with dose adjusted for body size. Neither approach should be treated as the default: the nasal route carries all of the trial evidence and less immunogenicity risk, while the injectable route is preferred by some prescribers for dose precision and independence from nasal mucosal condition. No head-to-head comparison exists in humans; rodent work comparing intranasal with intraperitoneal delivery found the pharmacological profile differs by route rather than being simply equivalent.

• Who popularised each approach: The nasal protocol originates with the Institute of Molecular Genetics of the Russian Academy of Sciences and the V.V. Zakusov Research Institute of Pharmacology, whose investigators (Myasoedov, Seredenin, Zozulya, Medvedev and colleagues) designed the compound and ran every registration trial. The injectable approach has no single originator in the literature; it emerged from United States compounding-pharmacy and peptide-clinic practice in the 2010s and is documented in practitioner interviews rather than in published protocols.

• Best time of day: Morning and early afternoon. Selank’s reported antiasthenic and mildly activating component argues against evening dosing, and the three-times-daily nasal schedule is conventionally spread across waking hours with the last dose in the late afternoon. There is no evidence of sleep disruption from evening dosing, but there is also no reason to place a stimulating agent near bedtime.

• Half-life and what follows from it: Approximately 2 minutes in blood. This is short enough that plasma levels are irrelevant to scheduling: the clinical effect persists for days after a course ends, which means dosing frequency is driven by the need to repeat a trigger for downstream gene-expression and receptor changes, not by maintaining a blood concentration. It is also why missing a single dose has little practical consequence.

• Single versus split dosing: Split. The registered protocol divides the daily dose into three administrations, and the nasal route imposes a practical ceiling on volume per instillation, since more than 2 to 3 drops per nostril simply runs off. Injectable protocols use a single daily dose, which is a route-driven convenience rather than a pharmacological argument.

• Genetic polymorphisms influencing protocol: No pharmacogenetic guidance exists. The practically important point is negative: because Selank is not metabolised by cytochrome P450 enzymes, the CYP2C9, CYP2D6, and CYP3A4 variants that drive dose adjustment for most psychotropic drugs have no bearing on Selank dosing. COMT and OPRM1 variants are mechanistically plausible modifiers of response but have never been tested and cannot inform dose selection.

• Sex-based differences in dosing: None established. The registration trials used a fixed dose for both sexes without weight adjustment and published no sex-stratified response data. Injectable protocols that adjust for body weight will produce systematically different exposure between sexes; the nasal protocol will not.

• Age-related considerations: No age-adjusted dosing exists, and no published trial enrolled a dedicated older cohort. Practical adjustment for adults at the older end of the range is downward on absorption grounds rather than clearance grounds: age-related nasal mucosal thinning and dryness make nasal delivery erratic, so beginning at 2 drops into each nostril twice daily and assessing tolerability before moving to three times daily is the conservative sequence. Concurrent medication review matters more than dose in this group.

• Baseline biomarkers influencing response: Elevated hs-CRP and interleukin-6 mark the subgroup with something for the immune arm of the mechanism to normalise. A high baseline anxiety score marks the subgroup in whom the registration trials found the largest effect. Normal thyroid-stimulating hormone, ferritin, and fasting insulin are confirmed first, because abnormalities in any of them generate the same symptoms Selank is being used for.

• Pre-existing conditions influencing response: Chronic rhinitis, nasal polyps, deviated septum, and habitual decongestant use all reduce and destabilise nasal absorption and argue for reconsidering the route. Untreated obstructive sleep apnoea, hypothyroidism, and iron deficiency will cap the achievable response regardless of dose. Concurrent benzodiazepine use changes the protocol entirely, since the only positive add-on data come from a supervised benzodiazepine-reduction context.

Discontinuation & Cycling

• Lifelong or short-term: Short-term by design. Selank was developed, tested, and registered as a 14-day course for an episode of anxiety or asthenia, not as a maintenance therapy. Every safety and efficacy observation in humans comes from that time frame. Treating it as an indefinite daily longevity supplement extends use far beyond any evidence, and is the single largest gap between how the compound was studied and how it is now used.

• Known withdrawal effects: None reported. Across the published human courses no withdrawal syndrome, rebound anxiety, or discontinuation symptom was described, and the anxiolytic effect was reported to persist for approximately a week after the last dose rather than dropping off. This contrasts sharply with benzodiazepines, and is one of the compound’s genuine points of interest. The qualifier is that none of these studies was designed to detect withdrawal, and pharmacologists outside the developing network have argued specifically that dependence liability for a compound acting on both GABA-A and opioid signalling has never been formally assessed.

• Tapering protocol: Not required, and not used in any published protocol. Courses were stopped abruptly at day 14 or day 30 without taper and without reported consequence. The one situation where tapering matters is the reverse case: where Selank has been added to a benzodiazepine specifically to support reduction of that benzodiazepine, the benzodiazepine still requires its own slow taper, and Selank does not remove that need.

• Cycling for maintaining efficacy: No tolerance has been reported, so there is no efficacy-driven reason to cycle. The reason to cycle is exposure limitation, not efficacy preservation: keeping total exposure inside the window over which safety has actually been observed. The pattern reported by prescribing clinicians is one month on followed by one month off, roughly six cycles per year; the pattern with published human data behind it is a 14 to 30 day course repeated only when symptoms recur.

• Deciding when to stop entirely: Absence of a clear effect after a full 14-day course at the standard dose is the most common and most useful stopping signal, because the registration data describe onset within days rather than weeks, with a subset of rapid responders improving in the first three days. Continuing beyond one unsuccessful course accumulates the risks without the offsetting benefit.

Sourcing and Quality

• Product form and grade: Two categories exist and they are not interchangeable. The registered Russian pharmaceutical product is a 0.15% nasal drop solution manufactured under pharmaceutical controls by Peptogen (ZAO Peptogen, Moscow), the enterprise established by the Institute of Molecular Genetics to produce it, and distributed there under the Selank brand name. Everything else sold internationally is freeze-dried (lyophilised) powder supplied for laboratory use, labelled not for human consumption, and produced without the identity, purity, sterility, or endotoxin controls that apply to medicines. Grade is the single most consequential sourcing decision for this compound.

• What to look for in a certificate of analysis: A lot-specific certificate from an independent laboratory, not the vendor’s own, referencing the exact lot number printed on the vial. A complete certificate reports identity confirmed by mass spectrometry, purity by high-performance liquid chromatography of 98% or greater, water content, and residual solvent. For any material intended for injection it additionally reports sterility and bacterial endotoxin results. A generic product-level certificate, an undated certificate, or one without a lot number provides no assurance.

• Third-party testing is the only meaningful verification: Because there is no regulatory oversight of this supply chain, independent analytical laboratories that will test a purchased vial on request (mass spectrometry for identity, chromatography for purity) are the only route to knowing what is in it. Sending a sample from a new lot for independent testing before use is the practice that separates careful users from hopeful ones, and it is the only defence against the mislabelled and under-dosed product repeatedly found in unregulated peptide markets.

• Regulated channels and their limits: In the United States, a licensed 503A compounding pharmacy (one operating under the section of federal law that governs prescription-specific compounding) working against a valid prescription is the only defensible domestic source, and accreditation by the Pharmacy Compounding Accreditation Board (PCAB, the voluntary programme that inspects compounding pharmacies against quality standards) is the practical marker separating a reputable pharmacy from the rest, but Selank sits in a contested regulatory position: the FDA carries selank acetate (TP-7) on its page of bulk drug substances that may present significant safety risks, in the withdrawn-nomination table, and unlike BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, and Epitalon, Selank was not among the substances reviewed at the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting, so its status remains unresolved rather than favourably settled. Importing the registered Russian product for personal use raises its own legal questions in most jurisdictions.

• Storage and handling as a quality issue: Freeze-dried powder is kept refrigerated and protected from light; reconstituted solution is held at approximately 4°C (39°F) and discarded after about 30 days. The vial is left unshaken, because agitation promotes the peptide aggregation that underlies the immunogenicity concern. Quality that survives manufacture is routinely destroyed by handling.

• Vendor red flags: Claims of FDA approval, absence of any certificate of analysis, refusal to supply lot numbers, prices far below the market for a peptide of this synthesis complexity, marketing that presents the compound as a dietary supplement, and pre-mixed multi-peptide blends whose individual contents cannot be verified. The pre-mixed blends are particularly problematic because they make it impossible to attribute either an effect or an adverse reaction to any single component.

Practical Considerations

• Time to effect: Fast by the standards of psychoactive compounds. The registration data describe anxiolytic effect emerging within the first days of a course, with a rapid-responder subgroup improving within roughly three days and the full effect established across the 14-day course. Practitioner reports place noticeable calm and mental clarity in the first one to two weeks, with cognitive effects, where they occur, taking four to six weeks. Anyone who has completed a proper 14-day course at the standard dose without effect has the answer.

• Common pitfalls: Buying laboratory-grade powder and treating it as medicine; stacking Selank with two or three other peptides simultaneously so that nothing can be attributed; expecting an acute, benzodiazepine-like calming effect within an hour and abandoning the compound when it does not arrive; dosing in the evening despite the activating component; reconstituting with ordinary water rather than bacteriostatic water (sterile water containing a preservative that limits bacterial growth); shaking the vial; running open-ended daily use instead of defined courses; and using it to mask an untreated thyroid disorder, iron deficiency, or sleep disorder that produces identical symptoms.

• Regulatory status: Not approved by the FDA or by any Western regulator, and not lawfully marketed as a dietary supplement in the United States, the European Union, or the United Kingdom, since a synthetic peptide drug does not meet the definition of a dietary ingredient. It is a registered prescription medicine only in Russia. The FDA carries selank acetate (TP-7) on its page of bulk drug substances that may present significant safety risks in compounding, in the table of withdrawn nominations rather than the active category 2 list, and it was not among the peptides reviewed for the 503A bulks list at the July 2026 advisory committee meeting. For competitive athletes, Selank is not individually named on the World Anti-Doping Agency (WADA, the body that sets international anti-doping rules) Prohibited List but falls under the S0 category covering any pharmacological substance without current approval by a governmental regulatory health authority, and is therefore prohibited at all times.

• Cost and accessibility: Cost is not the barrier. The registered Russian nasal solution costs roughly 10 to 20 United States dollars per bottle in its home market, and laboratory-grade powder typically runs 30 to 80 dollars per month of use. The binding constraints are legal and logistical: obtaining pharmaceutical-grade product outside Russia requires either a compounding pharmacy willing to work with a substance on the FDA’s safety-risk list, or personal importation of a foreign prescription medicine. Independent third-party testing of a purchased lot adds a further 50 to 150 dollars, a small fraction of total cost relative to the identity and purity uncertainty it resolves.

Interaction with Foundational Habits

• Sleep: Indirect and probably favourable, with no direct sedative effect. Selank produced no hypnosedation in the human trials and, unlike benzodiazepines, has not been reported to increase sleep duration or produce next-day grogginess; the add-on trial specifically recorded reduced excessive sleep duration when Selank was combined with a benzodiazepine. The proposed mechanism for any sleep benefit is reduction of pre-sleep anxious arousal rather than sedation. No polysomnography (sleep-laboratory recording of brain and body activity through the night) has ever been performed on Selank, so effects on sleep architecture are unknown. Practical consideration: schedule the last dose no later than late afternoon, given the reported activating component.

• Nutrition: Essentially none, in either direction. Selank is a peptide cleared by peptidases and is not known to deplete any vitamin or mineral, and no dietary pattern has been shown to modify its effect. The nasal route bypasses the gastrointestinal tract entirely, so food timing is irrelevant to dosing, which is a practical advantage over oral anxiolytics. One indirect consideration applies: the immune and inflammatory pathways Selank acts on are also strongly modified by diet, so a high-inflammatory dietary pattern works against the mechanism the compound is being used to engage. Animal work suggesting Selank preserves gut mucosal structure and shifts colonic microbiota under chronic stress has no human counterpart, so it carries no established dietary implication.

• Exercise: Direct interaction not demonstrated in either direction; the relationship is practical rather than physiological. Selank is not anabolic, has no reported effect on muscle protein synthesis, and there is no evidence that it blunts the training adaptations that non-steroidal anti-inflammatory drugs are suspected of blunting, despite its effects on inflammatory signalling. No timing relative to training sessions has been studied, and none is indicated. The consideration that does matter is regulatory: for anyone competing under anti-doping rules, Selank is prohibited at all times as a non-approved substance, and a training-related use is not a defence.

• Stress management: Direct and potentiating, and this is the domain where Selank and behavioural practice overlap most. Selank’s entire mechanistic case is stress-related, with animal work showing protection of gut, liver, and cytokine profiles under chronic restraint and social stress, and human work showing altered coupling between the amygdala and temporal cortex within twenty minutes of dosing (Panikratova et al., 2020). Because the pharmacological effect is short-lived while the behavioural interventions build durable capacity, cognitive behavioural therapy, structured breathing practice, and consistent recovery are complements rather than alternatives. The specific practical risk is substitution: using a 14-day peptide course in place of a behavioural intervention with far stronger evidence produces a temporary result and no durable change.

Monitoring Protocol & Defining Success

Baseline testing. Monitoring protocols place a full baseline panel and a documented symptom score before the first dose. This serves two purposes that cannot be recovered later: it screens out the treatable conditions that produce anxiety and fatigue and would otherwise be masked, and it makes any subsequent abnormality attributable. With an unregulated product this is the only mechanism for distinguishing a peptide effect from background variation.

Ongoing monitoring. The core panel is repeated at the end of the first course (day 14 to 30), again at 3 months where courses are being repeated, and then every 6 to 12 months across repeated cycles. Symptom scores are recorded weekly during a course and at the same time of day. Where an injectable preparation is used, a physical check of injection sites accompanies each dose.

The panel below uses several standard abbreviations: GAD-7 (Generalized Anxiety Disorder 7-item scale, a short questionnaire that scores anxiety severity), PSS-10 (Perceived Stress Scale, a 10-question measure of how stressful recent life has felt), IL-6 (interleukin-6, a signalling protein released by immune cells), CBC (complete blood count, the standard count of red cells, white cells, and platelets), CMP (comprehensive metabolic panel, the standard blood chemistry set covering kidney, liver, and electrolyte status), ALT and AST (alanine aminotransferase and aspartate aminotransferase, two liver enzymes that leak into blood when liver cells are stressed), TSH (thyroid-stimulating hormone, the pituitary signal that drives the thyroid), free T4 (free thyroxine, the unbound form of the main thyroid hormone), and HbA1c (haemoglobin A1c, a measure of average blood sugar over roughly three months).

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Generalized Anxiety Disorder 7-item score (GAD-7)	0-4	Quantifies the primary target symptom	A validated seven-question self-report scale, not a blood test; recorded at the same time of day and the same weekday; the conventional threshold for clinically significant anxiety is 10 or above
Perceived Stress Scale (PSS-10)	Below 14	Captures subjective stress load, which anxiety scales miss	Ten-item self-report questionnaire covering the past month; less sensitive to short-term change than GAD-7, so it is used at baseline and end of course only
High-sensitivity C-reactive protein (hs-CRP)	Below 1.0 mg/L, ideally below 0.5 mg/L	General marker of body-wide inflammation; the most accessible read on the claimed immune-modulating effect	Conventional laboratories report anything below 3.0 mg/L as normal, a far looser target; invalid within 2-3 weeks of infection, injury, vaccination, or unusually hard training
Interleukin-6 (IL-6)	Below 1.5 pg/mL	A signalling protein released by immune cells that Selank has been reported to shift in both directions	Conventional laboratories report anything up to roughly 5-7 pg/mL as normal, several times the functional target; expensive and biologically variable; drawn fasting before 10 a.m.; interpreted only alongside hs-CRP, never alone
Complete blood count with differential (CBC)	Lymphocytes 20-40% of white cells; neutrophil-to-lymphocyte ratio below 2.0	Detects immune shifts and screens for occult infection before an immune-active peptide is introduced	Fasting not required; best paired with hs-CRP drawn on the same sample
Comprehensive metabolic panel with liver enzymes (CMP, including ALT and AST)	Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 10-26 U/L	Baseline liver and kidney function, essential before any non-pharmaceutical injectable	Fasting 8-12 hours; conventional upper limits for ALT of 40-55 U/L are far looser than functional targets, so a “normal” result can still represent a meaningful rise from baseline
Thyroid-stimulating hormone (TSH) with free thyroxine (free T4)	TSH 0.5-2.0 mIU/L; free T4 in the mid-to-upper reference range	Thyroid dysfunction is a common, treatable cause of anxiety and fatigue that Selank would mask rather than correct	Drawn fasting before 10 a.m.; the conventional TSH range extends to 4.5 mIU/L, which tolerates substantial subclinical dysfunction
Ferritin	50-150 ng/mL in women; 50-200 ng/mL in men	Depleted iron stores reproduce the fatigue and low drive Selank is used for	Conventional laboratories flag deficiency only below roughly 15-30 ng/mL, far under the functional floor of 50; rises with inflammation, so it is read alongside hs-CRP; a normal ferritin with a raised hs-CRP can still conceal iron deficiency
25-hydroxyvitamin D	40-60 ng/mL	Low status is associated with low mood and impaired immune regulation, both relevant to the claimed mechanism	The conventional sufficiency threshold is 30 ng/mL, below the functional target; fasting not required; changes in supplementation take 8-12 weeks to show, so earlier retesting is uninformative
Fasting glucose and fasting insulin	Glucose 75-85 mg/dL; insulin 2-5 µIU/mL	Blood-sugar instability produces symptoms indistinguishable from anxiety; animal work reports Selank affects glucose and lipids	Conventional laboratories report fasting glucose up to 99 mg/dL and fasting insulin up to about 25 µIU/mL as normal, both far looser than the functional targets; fasting 8-12 hours; paired with haemoglobin A1c (HbA1c, a measure of average blood sugar over roughly three months) for a fuller picture
Morning serum cortisol	10-15 µg/dL at 8 a.m.	Objective read on the stress-hormone axis Selank is claimed to buffer	The conventional 8 a.m. range of roughly 5-25 µg/dL is much wider than the functional target; time of draw is critical and must be identical between tests; a four-point salivary series reflects the daily rhythm better but costs more

Qualitative markers. These carry more weight than the laboratory panel for this compound, because the primary claimed effects are subjective and no blood marker tracks them. Each is recorded on a simple 1-10 scale at the same time each day.

• Anxious arousal: frequency and intensity of racing thoughts, physical tension, and anticipatory worry.
• Sleep quality: time to fall asleep, night wakings, and how restored mornings feel, distinguished from total sleep duration.
• Cognitive clarity: ease of sustained focus, word-finding, and mental fatigue late in the working day.
• Energy and drive: willingness to initiate demanding tasks, which is the specific antiasthenic claim and the one most easily confused with placebo.
• Emotional range: whether calm arrives with or without flattening; benzodiazepine-like emotional indifference is the effect Selank is specifically claimed to avoid, and its presence is a signal to stop.
• Local tolerance: nasal stinging, dryness, congestion, or bleeding for the nasal route; site redness, swelling, or hardening for the injectable route.

Defining success. A course has succeeded if the anxiety score falls by a meaningful margin (a drop of 5 or more points on the GAD-7 is the conventional threshold for clinically important change), qualitative energy and clarity improve without emotional flattening or sedation, and no local or systemic adverse signal appears. A course has failed if 14 days at the standard dose produce no clear change in either the score or the qualitative markers, and continuing beyond that accumulates risk without benefit.

Emerging Research

Framed for an adult deciding whether the evidence base is likely to become more or less favourable over the next few years, rather than for a population-level policy question.

• No registered clinical trials: A direct search of ClinicalTrials.gov in August 2026 returned no registered interventional or observational study of Selank, under any spelling or as any intervention. This is the single most important fact in this section. Seventeen years after Russian registration, there is no ongoing trial anywhere in the international registry that could change the evidence grade for any claimed benefit, and no sponsor has stepped forward to run one. Anyone using Selank should expect the evidence base to remain roughly where it is.

• Regulatory review of sibling peptides: The FDA’s Pharmacy Compounding Advisory Committee met on July 23-24, 2026 to evaluate BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, and Epitalon for inclusion on the list of substances permitted in pharmacy compounding. Selank was not on the agenda, but Semax comes from the same Russian institute and shares the same evidence-base structure, so the agency’s published analysis of Semax is the closest thing to an independent regulatory assessment of this class of compounds and will shape how Selank is treated. This is the development most likely to change Selank’s practical availability in the next two years, in either direction.

• Immune and cytokine work strengthening the case: Groups outside Moscow, notably at Astrakhan State Medical University, are extending the cytokine work into stress models, reporting normalisation of interleukin-1-beta, interleukin-6, tumour necrosis factor-alpha, and transforming growth factor-beta-1 under social stress (Yasenyavskaya et al., 2021). This work is not independent of the originating network: the Institute of Molecular Genetics supplies the peptide, and its principals Myasoedov and Andreeva appear as co-authors, so the same conflict of interest that runs through the anxiety literature applies here. Because inflammatory signalling that rises with age is the most credible longevity-relevant target for this compound, replication of these findings in humans would matter more for this audience than further anxiety data.

• Gut, microbiome, and organ-protection work: Studies from Kursk State Medical University, again carrying Institute of Molecular Genetics co-authorship, report that Selank preserves colonic mucosal structure and shifts colonic microbiota composition in chronically stressed rats (Mukhina et al., 2019), alongside parallel findings on hepatocyte function. This is an entirely new direction relative to the anxiolytic programme and could open a gut-barrier rationale, but it is at the earliest animal stage.

• Withdrawal and addiction applications: Work at the V.V. Zakusov Institute reports that Selank attenuates the aversive signs of morphine withdrawal in rats (Konstantinopolsky et al., 2022), extending earlier alcohol-withdrawal findings. This is mechanistically consistent with the enkephalin-preserving action and represents a plausible clinical development path, but it also sharpens the unresolved question about the compound’s own reinforcement potential.

• Neurodegeneration models: Selank has been tested alongside Semax in rats with 6-hydroxydopamine-induced parkinsonism (a standard chemical model of Parkinson’s disease), with reported behavioural effects (Slominsky et al., 2017). This is early, model-specific, and from the developing institute, but it is the direction in which a genuine longevity claim would have to be built.

• Evidence that could weaken the case: Two lines run against the compound. The first is analytical rather than experimental: the finding that the breakdown fragment Gly-Pro reproduces much of Selank’s effect on immune gene expression (Kolomin et al., 2014) raises the possibility that the designed heptapeptide is not the active agent, which would undercut the rationale for using it specifically. The second is the pharmacological critique from outside the Russian network arguing that a GABA-active, opioid-involved compound sold to consumers without approval requires formal abuse-liability assessment (Doyno & White, 2021); a positive finding there would reclassify Selank’s risk profile substantially.

• The decisive missing study: The gap that determines everything is a blinded, placebo-controlled trial of the registered nasal protocol run by investigators with no connection to the institutes that developed and patented the compound. Every current benefit grade in this review is capped by its absence, and no such study is registered, funded, or announced. There is also no commercial party with an incentive to run one: Selank is inexpensive, effectively unpatentable in its original form, and generates no revenue stream large enough to fund a trial, while institutional payers have a systematic interest in cheap generic benzodiazepines and antidepressants rather than in validating an additional agent.

Conclusion

Selank is a stabilised version of a natural immune-signalling peptide, developed and registered in Russia as a nasal treatment for anxiety. Its most consistently reported effect is a reduction in anxiety symptoms in people with diagnosed anxiety conditions, with an unusual profile for a calming agent: no reported drowsiness, memory dulling, or dependence. Effects on mood, drive, fatigue, and inflammatory signalling rest on thinner evidence, and the claims about memory, nerve-cell growth, gut protection, and metabolism rest on animal studies or theory alone.

The safety picture is shaped less by the molecule than by the supply chain. Outside Russia there is no approved product, and material sold for laboratory use only carries real uncertainty about identity, purity, and sterility. United States regulators list it among substances that may pose a risk of unwanted immune reactions, because such peptides can clump together and carry impurities, and say they lack the information needed to know whether it would harm people. Long-term human data are absent.

The evidence base also carries a structural conflict of interest: nearly all human and animal work originates from the Russian institutes that designed, patented, and produce the compound, and no independent group has replicated the clinical findings. No commercial sponsor or payer has a reason to fund neutral study of an inexpensive, unpatentable peptide. What remains is a compound with a believable way of working, a reassuring safety record in short studies, and an evidence base too narrow and too self-interested to settle the question.

Top - Benefits - Risks - Protocol